QED Therapeutics, a BridgeBio company
Registry sponsor category
Industry
- Other names
- QED Therapeutics, a BridgeBio company
- Company name
- QED Therapeutics, a BridgeBio company
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (14)
- A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- An Interventional Study of Infigratinib in Children With Hypochondroplasia
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- Infigratinib in Recurrent High-Grade Glioma Patients
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
- Phase I BLASST-3 Trial
- Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
- Prospective Clinical Assessment Study in Children With Hypochondroplasia
- Study of Infigratinib in Children With Achondroplasia
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer